<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>316</serviceExecutionTime><Drug id="55965"><DrugName>injectable protein based HCV infection therapies, Apollo Life Sciences</DrugName><DrugSynonyms><Name><Value>injectable protein based hepatitis C virus infection therapies, Apollo Life Sciences</Value></Name><Name><Value>injectable protein based HCV infection therapies, Apollo Life Sciences</Value></Name></DrugSynonyms><CompanyOriginator id="1005919">Apollo Life Sciences Pty Ltd</CompanyOriginator><CompaniesSecondary><Company id="1005919">Apollo Life Sciences Pty Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1005919" type="Company"><TargetEntity id="4295856816" type="organizationId">Apollo Consolidated Ltd</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="596">Injectable formulation</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-30T13:11:53.000Z</LastModificationDate><ChangeDateLast>2010-02-02T18:19:50.000Z</ChangeDateLast><AddedDate>2006-08-22T12:22:47.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1005919" linkType="Company"&gt;Apollo Life Sciences&lt;/ulink&gt; was investigating  injectable protein-based treatments for hepatitis C virus (HCV) infection [&lt;ulink linkID="685222" linkType="Reference"&gt;685222&lt;/ulink&gt;]. In May 2005, the company reported that preclinical studies were ongoing [&lt;ulink linkID="685222" linkType="Reference"&gt;685222&lt;/ulink&gt;]; in December 2007, these preclinical studies were still ongoing [&lt;ulink linkID="856585" linkType="Reference"&gt;856585&lt;/ulink&gt;]; however, by October 2008, the company was no longer trading and all research and development activities were presumed to have been discontinued  [&lt;ulink linkID="1071348" linkType="Reference"&gt;1071348&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By May 2005, the company had completed preliminary animal studies which suggested that one of its HCV infection candidates was less likely to induce neurological side-effects. At that time, preclinical studies were ongoing [&lt;ulink linkID="685222" linkType="Reference"&gt;685222&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1005919">Apollo Life Sciences Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-24T00:00:00.000Z</StatusDate><Source id="1071348" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1005919">Apollo Life Sciences Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-05-26T00:00:00.000Z</StatusDate><Source id="685222" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>